Ann C. Collier

Active 1984–2024

113
Papers
24,079
Citations
82
h-index
113
i10-index

Citations

Citations per year for Ann C. Collier1967: 1 citations1985: 5 citations1986: 10 citations1987: 6 citations1988: 17 citations1989: 11 citations1990: 38 citations1991: 59 citations1992: 69 citations1993: 58 citations1994: 43 citations1995: 53 citations1996: 68 citations1997: 84 citations1998: 100 citations1999: 91 citations2000: 111 citations2001: 78 citations2002: 93 citations2003: 89 citations2004: 107 citations2005: 94 citations2006: 81 citations2007: 99 citations2008: 108 citations2009: 130 citations2010: 168 citations2011: 215 citations2012: 216 citations2013: 200 citations2014: 211 citations2015: 143 citations2016: 151 citations2017: 128 citations2018: 93 citations2019: 681 citations2020: 522 citations2021: 438 citations2022: 283 citations2023: 202 citations2024: 337 citations2025: 126 citations2026: 6 citations1968–1984: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,043 citing papers, 42.2% of this breakdownUnited Kingdom: 496 citing papers, 6.9% of this breakdownCanada: 340 citing papers, 4.7% of this breakdownFrance: 243 citing papers, 3.4% of this breakdownSouth Africa: 217 citing papers, 3% of this breakdownAustralia: 216 citing papers, 3% of this breakdownItaly: 213 citing papers, 2.9% of this breakdownGermany: 191 citing papers, 2.6% of this breakdownSpain: 179 citing papers, 2.5% of this breakdownChina: 169 citing papers, 2.3% of this breakdownNetherlands: 164 citing papers, 2.3% of this breakdownSwitzerland: 158 citing papers, 2.2% of this breakdown
0%42.2%Other 22%

Fields

  • Medicine49.5%
  • Immunology and Microbiology40.7%
  • Biochemistry, Genetics and Molecular Biology3.1%
  • Neuroscience1.7%
  • Psychology1.1%
  • Mathematics0.9%
  • Other3%

Topics

  • HIV Research and Treatment19.7%
  • HIV/AIDS Research and Interventions13.6%
  • HIV/AIDS drug development and treatment10%
  • HIV-related health complications and treatments7.8%
  • Immune Cell Function and Interaction2.1%
  • Cytomegalovirus and herpesvirus research1.9%
  • Other44.9%

Coauthors

All papers

Open in search
  1. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Neurology 2010 cited by 2,318

  2. Efficacy of a Clinical Decision Rule to Enable Direct Oral Challenge in Patients With Low-Risk Penicillin Allergy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - JAMA Internal Medicine 2023 cited by 186

  3. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of NeuroVirology 2010 cited by 1,550

  4. The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Bruce D. Walker, Jonathan Z. Li - The Journal of Infectious Diseases 2018 cited by 205

  5. Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral Therapy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Davey M. Smith, Serena Spudich, Athe Tsibris - The Journal of Infectious Diseases 2020 cited by 148

  6. Neurocognitive Change in the Era of HIV Combination Antiretroviral Therapy: The Longitudinal CHARTER Study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , D. Franklin, R. J. Ellis, Thomas S. Alexander, T. Alexander, Edmund V. Capparelli, Robert K. Heaton, J. Hampton Atkinson, R. K. Heaton, Mark A. Dawson, Davey M. Smith, Christine Fennema‐Notestine, Michael Taylor, Rebecca J. Theilmann, Anthony Gamst, Clint Cushman, Ian Abramson, Florin Vaida, Thomas D. Marcotte, J. Marquie-Beck, J. McArthur, V. Rogalski, Susan Morgello, David M. Simpson, Letty Mintz, D. Simpson, Will Toperoff, Ann C. Collier, Christina M. Marra, Timothy A. Jones, Benjamin B. Gelman, Eleanor Head, David B. Clifford, M. Al-Lozi, D. Clifford, M. Al-Lozi, Mahlet Belachew - Clinical Infectious Diseases 2014 cited by 408

  7. Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Neurology 2014 cited by 308

  8. Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication

    Authors: , , , , , , , , , , , - AIDS 2010 cited by 288

  9. White matter damage, neuroinflammation, and neuronal integrity in HAND

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of NeuroVirology 2018 cited by 109

  10. Heavy Cannabis Use Associated With Reduction in Activated and Inflammatory Immune Cell Frequencies in Antiretroviral Therapy–Treated Human Immunodeficiency Virus–Infected Individuals

    Authors: , , , , , , , , , , , , , - Clinical Infectious Diseases 2017 cited by 115

  11. Long-Acting Injectable Antiretroviral Treatment Acceptability and Preferences: A Qualitative Study Among US Providers, Adults Living with HIV, and Parents of Youth Living with HIV

    Authors: , , , , , , , - AIDS Patient Care and STDs 2019 cited by 83

  12. Invasion of the Central Nervous System by Treponema pallidum: Implications for Diagnosis and Treatment

    Authors: , , , , , - Annals of Internal Medicine 1988 cited by 602

  13. Safety, Pharmacokinetics, and Antiviral Activity of AMD3100, a Selective CXCR4 Receptor Inhibitor, in HIV-1 Infection

    Authors: , , , , , , , , , , , , , , - JAIDS Journal of Acquired Immune Deficiency Syndromes 2004 cited by 362

  14. Defining Neurocognitive Impairment in HIV: Deficit Scores Versus Clinical Ratings

    Authors: , , , , , , , , , , , , , - The Clinical Neuropsychologist 2012 cited by 240

  15. Treatment of Human Immunodeficiency Virus Infection with Saquinavir, Zidovudine, and Zalcitabine

    Authors: , , , , , , , , , , , , , , - New England Journal of Medicine 1996 cited by 756

  16. Protective HIV-specific CD8+ T cells evade Treg cell suppression

    Authors: , , , , , , , - Nature Medicine 2011 cited by 214

  17. Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation

    Authors: , , , , , , , , , , , , , - PLoS Pathogens 2017 cited by 185

  18. Persistent HIV-infected cells in cerebrospinal fluid are associated with poorer neurocognitive performance

    Authors: , , , , , , , , , , , , , , , , , - Journal of Clinical Investigation 2019 cited by 121

  19. Brief Report: Weight Gain Following ART Initiation in ART-Naïve People Living With HIV in the Current Treatment Era

    Authors: , , , , , , , , , , , , , , , , , , , , , , - JAIDS Journal of Acquired Immune Deficiency Syndromes 2020 cited by 81

  20. U.S. patient preferences for long‐acting HIV treatment: a discrete choice experiment

    Authors: , , , , , , , , , - Journal of the International AIDS Society 2023 cited by 28

  21. The prevalence and incidence of neurocognitive impairment in the HAART era

    Authors: , , , , , , , , , - AIDS 2007 cited by 625

  22. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy

    Authors: , , , , , , , , , , , - AIDS 2011 cited by 414

  23. Cells producing residual viremia during antiretroviral treatment appear to contribute to rebound viremia following interruption of treatment

    Authors: , , , , , , , - PLoS Pathogens 2020 cited by 40

  24. Varied Patterns of Decay of Intact Human Immunodeficiency Virus Type 1 Proviruses Over 2 Decades of Antiretroviral Therapy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Journal of Infectious Diseases 2023 cited by 31